Dr. Ryan J. Sullivan on Frontline Immunotherapy Sequencing in Melanoma
Cancer Network spoke with Ryan J. Sullivan, MD, of Massachusetts General Hospital, about the debate between immunotherapy sequencing vs targeted therapy for melanoma.
Cancer Network spoke with Ryan J. Sullivan, MD, medical oncologist at Massachusetts General Hospital, about why immunotherapy sequencing rather than immunotherapy targeted therapy should be the frontline treatment for melanoma.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
![A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6b7c9a3270c71a70749ba86000cfc78a29d74309-2988x1702.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.")
Related Content
